METABOLIC THERAPY IN PATIENTS WITH ISCHEMIC STROKE

The article shows the world experience of metabolic therapy use in the treatment of ischemic stroke. The issue still remains prominent. The reasonability of prescribing metabolic drugs is not completely clear, its effectiveness has not been fully proved, despite numerous studies which show only trends. The article presents an overview of the most popular drugs of different pharmacological groups with a metabolic effect which affect different parts of the ischemic cascade. Ethylmethylhydroxypyridine succinate and cytoflavin have predominantly antihypoxic effect, improve functional outcome and neurological functions, and normalize overall well-being and adaptation. Cerebrolysin is a complex of low molecular weight biologically active peptides derived from the pig’s brain. It has a multimodal effect on the brain, helps to reduce the volume of cerebral infarction, restores neurologic functions and improves the functional outcome. Cortexin is a mixture of cattle brain polypeptides, also has a complex action that provides the most complete reversion of neurological deficit, improves cognitive functions and the functional outcome, reduces the level of paroxysmal convulsive readiness and improves bioelectric activity of the brain. Citicoline is a precursor of cell membrane key ultrastructures, contributes to significant reduction in the volume of cortical brain damage, improves cholinergic transmission, which results in better clinical outcome, even despite the questionable impact on the neurological status. Choline Alfoscerate is a precursor of choline, and the use of the drug significantly limits the growth of the cerebral infarction area starting from the first day of therapy, leads to reversion of neurological symptoms and achievement of rehabilitation goals. Actovegin is deproteinized derivative of calf blood, activates metabolism in tissues, improves trophism and stimulates regeneration. In a large study, it was shown that Actovegin improved cognitive function in patients who had experienced a stroke,. The drug does not significantly improve the neurological status of patients after a stroke, but it reduces the risk of the stroke development in the next 10 years. Thus, we analyzed mechanisms of medical substances action and data of experimental and clinical studies, including ones after thrombolytic therapy and with inclusion of drugs for primary and secondary prevention of ischemic stroke. The reasonability and effectiveness of prescribing a combination of drugs of different pharmacological groups affecting brain metabolism remains controversial, since the excessive drug treatment may have complications. The safety of metabolic therapy is in doubt, and some of authors views presented confirm the need for additional large independent studies.

1. Anatskaya L.N. A cerebral infarction in elderly patients. Zh Nevrol Psikhiatr Im S S Korsakova. 2011; (8–2: Stroke): 74–80. (In Russian).

2. Kulikov A., Abdrashitova G. Budget Impact Analysis of Cerebrolysin In The Treatment of Acute Ischemic Stroke of Moderate and Severe Degrees of Severity In The Russian Federation. Value Health. 2015; 18 (7): A699. PMID: 26533918. DOI: 10.1016/j.jval.2015.09.2612.

3. Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2016; 12: CD007026. PMID: 27918088. DOI: 10.1002/14651858.CD007026.pub4.

4. Handbook of Vidal. Medicinal preparations in Russia – 2017. Moscow: Vidal’ Rus Publ., 2017. 1240 p. (In Russian).

5. Yasnetsov V.V., Prosvirova E.P., Tsublova E.G., et al. Comparative studies of antihypoxic, neuroprotective and analgesic action of succinatecontaining drugs. Aviakosmicheskaya i ekologicheskaya meditsina. 2012; 46 (6):41–45. (In Russian).

6. Odinak M.M., Yanishevskiy S.N., Tsygan N.V., et al. The use of succinates for the correction of metabolic disorders in the penumbra in patients with stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113(12–2: Stroke): 55–60. (In Russian).

7. Skvortsova V.I., Stakhovskaya L.V., Nartsissov Ya.R., et al. Randomized double blind placebo-controlled study of Mexidol efficacy and safety in the treatment of ischemic stroke in the acute period. Zh Nevrol Psikhiatr Im S S Korsakova. 2006; (18–2: Stroke): 47–54. (In Russian).

8. Seregin V.I., Dronova T.V. The use of mexidol in the intensive treatment of acute severe ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115 (3–2: Stroke): 85–87. (In Russian).

9. Androfagina O.V., Kuznetsova T.V., Svetkina A.A. Mexidol in the rehabilitation of patients in the acute ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115 (12–2: Stroke): 77–79. (In Russian).

10. Kispaeva T.T. Preventive/therapeutic correction of the development and progression of cognitive deficit in patients after stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113(7): 76–79. (In Russian).

11. Novikova L.B., Sharafutdinova L.R., Sharapova K.M. The use of mexidol in acute period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113 (9): 83–85. (In Russian).

12. Lutskiy M.A. Efficacy of Mexidol in complex treatment of patients with ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2010; 110 (4–2: Stroke): 57–59. (In Russian).

13. Kurushina O.V., Barulin A.E., Konovalova O.V. Correction of psychoemotional and autonomic dysfunction in patients with ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113 (9–2: Stroke 2): 50–54. (In Russian).

14. Shchepankevich L.A., Nikolaev Yu.A., Dolgova N.A., Chipova D.T. Optimization of hypolipidemic therapy in patients with ischemic stroke and diabetes mellitus. Zh Nevrol Psikhiatr Im S S Korsakova. 2016; 116(2): 42–45. (In Russian).

15. Koval’chuk V.V. Neurometabolic therapy in secondary prevention of stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114(3): 24–28. (In Russian).

16. Chefranova Zh.Yu., Makotrova T.A., Udachin V.A., Koledintseva E.V. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2012; 112(4): 49–52. (In Russian).

17. Tsygan N.V., Trashkov A.P., Yakovleva V.A., et al. Characteristics of the regulation of neurotrophic mechanisms in ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115(7): 112–116. (In Russian).

18. Koval’chuk V.V, Khafizova T.L., Galkin A.S. The use of neurometabolic treatment in the complex rehabilitation in poststroke patients. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; (11–1): 61–66. (In Russian).

19. Rumyantseva S.A., Silina E.V., Tsukurova L.A., et al. Modern methods of energy homeostasis correction in elderly patients. Uspekhi gerontologii. 2014; 27(4): 746–752. (In Russian).

20. Rumyantseva S.A., Silina E.V., Chichanovskaya L.V., et al. Efficacy of antioxidant energocorreсtion in brain infarction (results of a multicenter randomized trial). Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114(10): 49–55. (In Russian).

21. Chichanovskaya L.V., Tsukurova L.A., Kovalenko A.L., et al. Performance evaluation of integrated cytoprotective therapy of different duration in patients with cerebral infarction. Eksperimental’naya i klinicheskaya farmakologiya. 2015; 78(1): 21–26. (In Russian).

22. Karakulova Yu.V., Selyanina N.V., Zhelnin A.V., et al. Effect of antioxidant therapy on neurotrophins and processes of rehabilitation after stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2016; 116(8): 36–39. (In Russian).

23. Sazonov I.E., Lavrent’eva I.V., Golovina N.P. The use of cytoflavin in reperfusion in ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2016; 116(3): 25–28. (In Russian).

24. Hassanein S.M., Deifalla S.M., El-Houssinie M., Mokbel S.A. Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial. J Clin Neurol. 2016; 12(1): 79–84. PMID: 26365023. DOI: 10.3988/ jcn.2016.12.1.79.

25. Plavinskiy S.L., Shabalkin P.I. A meta-analysis.Cerebrolisyn, Cortexin, Cellex, efficiency in vascular dementia, Alzheimer’’s disease and ischemic stroke. Meditsina. 2016; (2). Available at: http://fsmj.ru/015231. html (Accessed 28 February 2018) (In Russian).

26. Zhang L., Chopp M., Lu M., et al. Cerebrolysin dose-dependently improves neurological outcome in rats after acute stroke: A prospective, randomized, blinded, and placebo-controlled study. Int J Stroke. 2016; 11(3): 347–355. PMID: 26763925. DOI: 10.1177/1747493015625645.

27. Xue L.X., Zhang T., Zhao Y.W., et al. Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke. Exp Ther Med. 2016; 11(5): 2015–2020. PMID: 27168844. DOI:10.3892/etm.2016.3139.

28. Heiss W.D., Brainin M., Bornstein N.M. et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebocontrolled randomized trial. Stroke. 2012; 43(3): 630–636. DOI: 10.1161/ STROKEAHA.111.628537.

29. Muresanu D.F., Heiss W.D., Hoemberg V., et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016; 47(1): 151–159. PMID: 26564102. DOI: 10.1161/STROKEAHA.115.009416.

30. Chang W.H., Park C.H., Kim D.Y., et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurol. 2016; 16:

31. PMID: 26934986. DOI: 10.1186/s12883-016-0553-z. 31. Shishkova V.N., Zotova L.I., Malyukova N.G., et al. An assessment of cerebrolysin effect on BDNF level in patients with post stroke aphasia depending on carbohydrate metabolism disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115(5–1): 57–63. (In Russian).

32. Lang W., Stadler C.H., Poljakovic Z., et al. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke. 2013; 8(2): 95–104. PMID: 23009193. DOI: 10.1111/j.1747-4949.2012.00901.x.

33. Nazari S., Mazdeh M., Taheri M., et al. A double-blind, placebocontrolled and randomized trial of Cerebrolysin in patients with acute ischemic stroke in Iran. Glob Adv Res J Med Med Sci. 2015; 4(5): 235–239.

34. Chukanova E.I., Gusev E.I., Belousov D.Yu., et al. Results of multicenter randomized controlled clinical and economic study of acute ischemic stroke therapy with Cerebrolysin. Kachestvennaya klinicheskaya praktika. 2011; (3): 14–37. (In Russian).

35. Amiri-Nikpour M.R., Nazarbaghi S., Ahmadi-Salmasi B., et al. Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatr Dis Treat. 2014; (10): 2299–2306. PMID: 25516711. PMCID: PMC4263193 DOI: 10.2147/NDT. S75304.

36. Kulikov A.Yu., Abdrashitova G.T. Pharmacoeconomic analysis of treatment of patients with severe and moderate ischemic stroke (NIHSS Score > 12). Farmakoekonomika: Teoriya i praktika. 2015; 3(4): 30–40. (In Russian).

37. Alifirova V.M., Dadashev M.N., Doronin B.M. et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114(4): 41–46. (In Russian).

38. Stakhovskaya L.V., Meshkova K.S., Dadasheva M.N., et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke. Vestnik Rossiyskoy Voennomeditsinskoy akademii. 2012; 1(37): 238–244. (In Russian).

39. Belova L.A., Mashin V.V., Abramova V.V., et al. Efficacy of cortexin in acute and recovery periodes of hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2016; 116(10): 38–42. (In Russian)

40. Belova L.A., Mashin V.V., Abramova V.V., et al. Cognitive impairment in patients poluchennym ischemic stroke in the acute and early recovery periods in the process of neuroprotection low-dose drug cortexin. Zh Nevrol Psikhiatr Im S S Korsakova. 2016; 116(8–2: Stroke): 40–43. DOI: 10.17116/jnevro20161168240-43 (In Russian).

41. Belova L.A., Mashin V.V., Abramova V.V., et al. Effect of cortexin on the quality of life in the early rehabilitative period after hemispheric ischemic stroke. Klinicheskaya meditsina. 2016; 94(2):138–143. (In Russian).

42. D’yakonov M.M., Shabanov P.D. Long-term experience of low-dose peptide neuroprotection in medicine. Vestnik Kazakhskogo Natsional’nogo meditsinskogo universiteta. 2015; (2): 371–373. (In Russian).

43. Evzel’man M.A., Aleksandrova N.A. Cognitive disorders and their correction in patients with ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113 (10): 36–39. (In Russian).

44. Zyryanov S.K., Stakhovskaya L.V., Gil’deeva G.N., Meshkova K.S. Clinical and economical analysis of effectiveness of cortexin in patients with hemispheric ischemic stroke in acute and early recovery period in specialized vascular centers. Vestnik Rossiyskoy Voenno-meditsinskoy akademii. 2012; (3): 69–74. (In Russian).

45. Yavorskaya V.A., Flomin Yu.V., Grebenyuk A.V. Citicoline at Acute stroke: Mechanism of Action, Safety and Effectiveness (Scientific Review). Mezhdunarodnyy nevrologicheskiy zhurnal. 2011; 2: 98–104. (In Russian).

46. Álvarez-Sabín J., Román G.C. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sci. 2013; 3(3): 1395– 1414. PMID: 24961534. PMCID: PMC4061873. DOI: 10.3390/ brainsci3031395.

47. Starchina Yu.A. Use of cereton in neurological care. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2011; (2): 81–85. (In Russian).

48. Odinak M.M., Voznyuk I.A., Piradov M.A., et al. Multicentral pilot clinical trial of gliatilin in treatment of acute ischemic stroke. Annaly klinicheskoy i eksperimental’noy nevrologii. 2010; (1): 20–28. (In Russian).

49. Vinogradov O.I., Daminov V.D., Rybalko N.V. The use of choline alfoscerate (gliatiline) in patients with ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113(1): 43–45. (In Russian).

50. Mishchenko T.S., Mishchenko V.N., Lapshina I.A. Gliatilin in the Treatment of Post-Stroke Patients. Mezhdunarodnyy nevrologicheskiy zhurnal. 2016; 4(82): 25–31. (In Russian).

51. Mishchenko V.N., Lapshina I.A. Gliatilin in Treatment of Patients in the Recovery Period of Cerebral Stroke. Mezhdunarodnyy nevrologicheskiy zhurnal. 2011; 5(43): 101–108. (In Russian).

52. Onchul L. Gliatilin: a modern view on the problem of cholinergic therapy in the treatment of ischemic stroke. Meditsina neotlozhnykh sostoyaniy. 2015; 7(70): 53–55. (In Russian).

53. Amenta F., Carotenuto A., Fasanaro A.M., et al. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer’s Disease) Trial: interim results after two years of treatment. J Alzheimers Dis. 2014; 42 (Suppl 3): S281–288. PMID: 24898643. DOI: 10.3233/JAD140150.

54. Guekht A., Skoog I., Edmundson S., et al. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017; 48: 1262–1270. PMID: 28432265. PMCID: PMC5404405. DOI: 10.1161/ STROKEAHA.116.014321.

55. Meilin S., Machicao F., Elmlinger M. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J Cell Mol Med. 2014; 18(8): 1623–1630. PMID: 24797227. PMCID: PMC4190908. DOI: 10.1111/jcmm.12297.

56. Yakupov E.Z., Nalbat A.V. The measures of autonomic homeostasis as predictors of an individual risk of stroke and their dynamics during therapy with Actovegin. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115 (10-2: To help a practical doctor): 31–42. DOI: 10.17116/ jnevro201511510231-42 (In Russian).

57. Ershov V.I. Comparative aspects of using neuroprotectors in the management of patients with ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2011; 111 (8–2: Stroke): 41–44. PMID: 22224244.

58. Skoromets A.A., Koval’chuk V.V. Drug Rehabilitation in Stroke Patients. Mezhdunarodnyy nevrologicheskiy zhurnal. 2007. 2(12): 9–12. (In Russian).

59. Izhbul’dina G.I. Changes in the hemostasis system and free-radical lipid oxidation in the acute stage of ischemic stroke in patients on neuroprotection treatment. Zh Nevrol Psikhiatr Im S S Korsakova. 2012; 112 (3–2: Stroke): 31–37. (In Russian).

60. Kuznetsova E.B., Salina E.A., Sholomov I.I. The possibility of treatment of cognitive impairment in the complex therapy of patients with the consequences of cerebral infarction. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115 (11): 103–106. (In Russian).

61. Kukhtevich I.I., Aleshina N.I., Levashova O.A. The active neuroprotective therapy of acute carotid ischemic stroke of moderate severity. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114 (12–2: Stroke): 38–42. (In Russian).

62. Lo E.H. A new penumbra: transitioning from injury into repair after stroke. Nat Med. 2008; 14(5): 497–500. PMID: 18463660. DOI: 10.1038/ nm1735.

63. Pavlov I.E. Caution: Actovegin, Solcoseryl, Cortexin, Cerebrosolate! 2012. Avalable at: http://www.medkrug.ru/blog/display_entry/54283. (Accessed 28 February 2018). (In Russian).